Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
!!Link opens in a new tab
!!Search content at The Hebrew University of Jerusalem
Home
Profiles
Research units
Research output
Prizes
Therapeutic options in COVID-19
Ehud Horwitz
, Ofer Perzon
, Dror Mevorach
School of Pharmacy
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Therapeutic options in COVID-19'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Therapeutic Potential
100%
COVID-19
100%
Prophylactic Treatment
100%
Monoclonal Antibody
66%
Early Treatment
66%
Passive Immunization
66%
Staged Treatment
66%
Inflammatory Diseases
33%
Severe Disease
33%
Risk Factors
33%
Hospitalized Patients
33%
Potential Treatments
33%
Corticosteroids
33%
Antiviral Agents
33%
Anticoagulation
33%
Moderate to Severe
33%
Cytokine Storm
33%
Pulmonary Vasodilators
33%
High-risk Population
33%
Protonation
33%
Rescue Procedure
33%
Neuromuscular Blockade
33%
Adult Respiratory Distress Syndrome
33%
JAK Inhibitors
33%
Lung Involvement
33%
Oxygen Support
33%
Refractory Hypoxemia
33%
Severe Patients
33%
Alveolar Recruitment
33%
Critical Patients
33%
Interlukin-6
33%
Extracorporeal Membrane Oxygenation
33%
Medicine and Dentistry
COVID-19
100%
Monoclonal Antibody
66%
Passive Immunization
66%
Antivirus Agent
33%
Inflammatory Disorder
33%
Anticoagulation
33%
Peripheral Vasodilating Agent
33%
High Risk Population
33%
Hypoxemia
33%
Cytokine Storm
33%
Extracorporeal Membrane Oxygenation
33%
Neuromuscular Blocking
33%
Janus Kinase Inhibitor
33%
Acute Respiratory Distress Syndrome
33%
Lung
33%
Diseases
33%
Corticosteroid
33%